Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 952,300 shares, an increase of 14.4% from the December 15th total of 832,200 shares. Based on an average daily volume of 94,200 shares, the short-interest ratio is currently 10.1 days. Approximately 4.4% of the company’s stock are sold short.
Insider Transactions at Gyre Therapeutics
In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 16,054 shares of company stock valued at $185,897. Insiders own 19.52% of the company’s stock.
Institutional Investors Weigh In On Gyre Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp lifted its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the third quarter worth approximately $334,000. Finally, WINTON GROUP Ltd purchased a new stake in Gyre Therapeutics during the second quarter worth approximately $220,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.
Gyre Therapeutics Trading Up 1.4 %
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
- Five stocks we like better than Gyre Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- What is the S&P/TSX Index?
- Oilfield Leader SLB: An AI Name You Need to Know
- Why Are Stock Sectors Important to Successful Investing?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.